Routine assessment of PARP-1 expression in CRC biopsies is, therefore, strongly recommended to identify patients who might benefit from PARPi combination therapy, while patients with low PARP-1 expression might be suitable for application of other DDR inhibitors, with ATR [70] and RAD51 [71] as promising targets. The gene discussed is RAD51; the disease is colorectal carcinoma.